Chiasma partners acromegaly candidate Octreolin with Roche; terminated
Israeli biotech Chiasma Inc. has licensed Roche exclusive global rights to its lead orphan drug candidate, Phase III Octreolin (octreotide). The first indication for the peptide therapeutic will be acromegaly (a growth disorder caused by the pituitary gland producing excessive growth hormone in the body), and a second potential use may be in neuroendocrine tumors, which are also related to the increased presence of growth hormone.
- Drug Delivery
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com